The first step is to harmonize our regime with the European and U.S. regimes. I'm no expert on how the Asians operate, but I believe theirs is a more heterogeneous model. That step really comes second in my eyes.
I would like to come back to your first question on investments by major pharmaceutical companies in Canada.
I don't believe Canada specifically is being targeted in that area. The global pharmaceutical model is changing. We won't be seeing investments in major R&D structures in any country. Pfizer just closed its main facility in Kent, England. I would say we need to think about new models of cooperation with the pharmaceutical industry.
In my presentation, I mentioned the Structural Genomics Consortium, which is one of those models. Phase three of the program has begun, and the initiative represents a $50-million investment by the pharmaceutical industry. That is another tool, another model that should be considered, and I'm sure that Canada is very well-positioned to attract that kind of investment.